Compare · BDSX vs CNC
BDSX vs CNC
Side-by-side comparison of Biodesix Inc. (BDSX) and Centene Corporation (CNC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDSX and CNC operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $29.62B, about 185.3x BDSX ($159.9M).
- Over the past year, BDSX is up 154.8% and CNC is up 6.4% - BDSX leads by 148.4 points.
- CNC has been more active in the news (17 items in the past 4 weeks vs 6 for BDSX).
- CNC has more recent analyst coverage (25 ratings vs 7 for BDSX).
- Company
- Biodesix Inc.
- Centene Corporation
- Price
- $15.29-0.20%
- $58.97-1.71%
- Market cap
- $159.9M
- $29.62B
- 1M return
- +34.95%
- +10.11%
- 1Y return
- +154.83%
- +6.44%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 17
- Recent ratings
- 7
- 25
Biodesix Inc.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest BDSX
- SEC Form EFFECT filed by Biodesix Inc.
- SEC Form S-3 filed by Biodesix Inc.
- Biodesix to Participate in Upcoming Investor Conferences
- SEC Form 8-K filed by Biodesix Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biodesix Inc.
- Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
- SEC Form 10-Q filed by Biodesix Inc.
- Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biodesix Announces First Quarter 2026 Results and Highlights
- SEC Form SCHEDULE 13G filed by Biodesix Inc.
Latest CNC
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Five Stars: Health Net Recognized by USA TODAY for Customer Service; Only California-Based Health Insurer Recognized with Highest Rating
- SEC Form 4 filed by Group President, Medicare&Spec Carson Michael A
- Centene upgraded by Deutsche Bank with a new price target
- New insider Finke Daniel P claimed ownership of 228,127 shares (SEC Form 3)
- New insider Carson Michael A claimed ownership of 123,707 shares (SEC Form 3)
- Centene Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update
- Director Tanji Kenneth was granted 3,992 shares, increasing direct ownership by 50% to 11,909 units (SEC Form 4)
- Director Samuels Theodore R. Ii was granted 3,992 shares, increasing direct ownership by 19% to 24,748 units (SEC Form 4)
- Director Ford Monte E was granted 3,992 shares, increasing direct ownership by 37% to 14,827 units (SEC Form 4)